Alyeska Investment Group
ARTV

Alyeska Investment Group’s Artiva Biotherapeutics ARTV Stock Holding History

Alyeska Investment Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Hold
100,000
– – ﹤0.01% 586
2025
Q4 		$429K Hold
100,000
– – ﹤0.01% 565
2025
Q3 		$287K Hold
100,000
– – ﹤0.01% 570
2025
Q2 		$151K Hold
100,000
– – ﹤0.01% 540
2025
Q1 		$300K Hold
100,000
– – ﹤0.01% 483
2024
Q4 		$1.01M Hold
100,000
– – ﹤0.01% 496
2024
Q3 		$1.54M Buy
+100,000
New +$1.16M 0.01% 437

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Alyeska Investment Group's ARTV Position: Q1 2026 in Review

Alyeska Investment Group held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 100,000 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #586.

Alyeska Investment Group first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.54M in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Alyeska Investment Group held 100,000 shares of Artiva Biotherapeutics worth $644K as of Q1 2026.
  • Alyeska Investment Group left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #586 holding.
  • Alyeska Investment Group first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Alyeska Investment Group's Artiva Biotherapeutics position peaked at $1.54M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.